Chabner Colloquium 2016

Program Brochure (PDF)
Abstract Book

Session 1:

New Insights Into Cancer Drug Resistance

Epigenetic Mechanisms of Tumor Initiation and Evolution

Bradley E. Bernstein, MD, PhD

Developing Therapies for Transcriptionally Addicted Tumors

Nathanael Gray, PhD

Session 2:

Targets That Defy Effective Therapy

Optimal MAPK Inhibition as a Key Component of Therapeutic Strategies for KRAS Mutant Cancers

Ryan B. Corcoran, MD, PhD

Session 3:

Hematologic Malignancies

FLT3 Inhibitors in the Therapy of Acute Myeloid Leukemia

Richard M. Stone, MD

Dihydroorotate Dehydrogenase: An Unexpected Metabolic Vulnerability in Acute Myeloid Leukemia

David B. Sykes, MD, PhD

Session 4:

Fellows Forum

Genomics of a Mitochondria-Rich Tumor

Raj Gopal, MD, PhD

Generation of Models of Human Hematologic Malignancies Using CRISPR Genome Engineering
Zuzana Tothova, MD, PhD

Session 6:

Neo-antigens and the Immune Response

T-Cell Therapy: Current Applications and Future Directions

Marcela V. Maus, MD, PhD

Addressing Cancer Clonal Heterogeneity: Developing Personalized Neoantigen-Based Cancer Vaccines

Catherine J. Wu, MD

Session 7:

Molecular Tumor Board

Moderator: Aditya Bardia, MD, MPH

Panelists: Darrell Borger, PhD; Leif W. Ellisen, MD, PhD; Justin F. Gainor, MD